Every SEC Form 3/4/5 on record for this filer (CIK 1753055) — 5 issuers, 37 transactions. Section-16 filings only: what they filed, not a biography, and titles are as filed on their latest form at each issuer.
| Ticker | Company | Role as filed | On file | Forms | Open-market net |
|---|---|---|---|---|---|
| BMY | BRISTOL MYERS SQUIBB CO | President, RayzeBio Org. | 2024-03-04 → 2026-03-12 | 10 | −$3,702 |
| MURA | Mural Oncology plc | Director | 2023-11-07 → 2025-12-05 | 6 | — |
| MRTX | Mirati Therapeutics, Inc. | EVP, Chief Commercial Officer · lapsed | 2020-01-08 → 2024-01-23 | 17 | −$2M |
| SURF | Surface Oncology, Inc. | Director · lapsed | 2021-12-16 → 2022-06-10 | 3 | — |
| HALO | HALOZYME THERAPEUTICS, INC. | SVP, Chief Commerical Officer · lapsed | 2018-09-14 → 2019-10-01 | 4 | — |
| Ticker | Date | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| BMY | 2025-05-09 | Sell | 97 | $38.01 | $3,702 | — |
2 of 5 issuers are covered and open a security page; the rest are on file here only.